Sulforaphane activates anti-inflammatory microglia, modulating stress resilience associated with BDNF transcription.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and in vitro laboratory study
PubMed 34272506 · doi:10.1038/s41401-021-00727-z
What was done
Researchers evaluated the mechanisms of sulforaphane (SFN) on stress resilience and depression-like behavior using a stressed mouse model and cultured BV2 microglial cells. They examined microglial inflammatory phenotypes, brain-derived neurotrophic factor (BDNF) transcription, Nrf2 and MeCP2 expression, and dendritic spine morphology.
What was found
The abstract reports directional mechanistic findings without numerical values or effect sizes. SFN conferred stress resilience, upregulated BDNF, rectified abnormal inflammatory cytokine levels, and restored altered dendritic spine morphology in stressed mice. In BV2 microglial cells and stressed mice, SFN shifted microglia from a pro-inflammatory to an anti-inflammatory phenotype, activated Nrf2 binding to the BDNF exon I promoter, and decreased levels of the transcriptional suppressor MeCP2.
Why it matters
The study outlines a microglial Nrf2/MeCP2/BDNF regulatory pathway that may explain how sulforaphane confers stress resilience in rodents. It offers preclinical mechanistic support for investigating Nrf2 inducers in stress-related mood disorders.
Limits
All findings are limited to mouse models and immortalized cell lines (BV2), which may not fully reflect human neurobiology or depression pathology. The abstract provides no quantitative data, sample sizes, dosage details, or behavioral metrics.
Cited by
- supports Sulforaphane upregulates brain-derived neurotrophic factor (BDNF).